Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | PRKDC | P78527 | 1/20 | 0.60 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.60 |
| ▸ | AKT1 | P31749 | 3/20 | 0.56 |
| ▸ | AKT2 | P31751 | 3/20 | 0.56 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590192 | 1.00 | PIK3CA (0.60) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30858045 | 0.88 | PIK3CA (0.47) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30784473 | 0.88 | PIK3CA (0.59) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL25531714 | 0.87 | AKT1 (0.71) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL26137008 | 0.86 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL25359156 | 0.82 | AKT1 (0.77) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL26137117 | 0.82 | AKT1 (0.77) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30590246 | 0.82 | AKT1 (0.77) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30590259 | 0.82 | AKT1 (0.64) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL26130497 | 0.82 | AKT1 (0.64) | PIK3CAPIK3CBMTORPRKDCPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124422-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2024-04-18 | — | — | US | claimed |
| WO-2023192416-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-10-05 | — | — | WO | claimed |
| US-20240124422-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2024-04-18 | — | — | US | disclosed |
| WO-2023192416-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192416-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124422-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PIK3CA, PIK3CD, PIK3R5 | PIK3CA 1/4885PIK3CB 6/4885MTOR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.